SF3B1 and myeloproliferative neoplasm: The SF3B1 spliceosome mutation is commonly a founder mutation in MDS/MPN-RS-T, and thus, the 2022 ICC recognized the mutation as a requirement in the diagnosis of MDS/MPN-T-SF3B1, as mentioned [3,29].